This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Ferrie, L. Articles by McQuade, R. Search for Related Content PubMed PubMed Citation Articles by Ferrie, L. Articles by McQuade, R. Social Bookmarking                   What's this?

Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat

Allan H. Young

Richard McQuade

Psychobiology Research Group, School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, The Medical School, Newcastle upon Tyne, UK

Bipolar affective disorders can be successfully treated with long-term use of the mood stabilizer lithium. However, discontinuation of lithium treatment is followed by a high incidence of manic episodes. In the present study, we attempted to identify neurobiological changes that might mediate this rebound mania. In vivo microdialysis in the anaesthetized rat and in situ hybridization histochemistry were used to study the effect of chronic lithium treatment and withdrawal from chronic lithium treatment on presynaptic dopamine (DA) function. Rats were maintained for 28 days on a lithium diet or control diet. The lithium-withdrawn treatment group had their lithium diet substituted for control diet from day 25 of the treatment period. Microdialysis probes were implanted in the shell of the nucleus accumbens and both basal extracellular DA levels and DA levels in the presence of the DA uptake inhibitor bupropion (1 µM) were collected. Basal DA levels did not differ between any of the treatment groups. However, during local perfusion of bupropion, the increase in DA was significantly attenuated in the lithium-treated animals compared to controls or lithium-withdrawn animals. In situ hybridization of DA transporter mRNA in the ventral tegmental area revealed no difference in the abundance of this mRNA in any of the groups. These data suggest that there is impaired DA release in rats during chronic lithium treatment, but DA release returns to normal levels on withdrawal from lithium treatment, and is therefore unlikely to underlie the rebound mania associated with lithium withdrawal.

Key Words: bupropion • dopamine • in vivo microdialysis • lithium • lithium withdrawal • nucleus accumbens

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Ryan and J. T. Slevin Restless Legs Syndrome Journal of Pharmacy Practice, December 1, 2007; 20(6): 430 - 448. [Abstract] [PDF]

				K. Roybal, D. Theobold, A. Graham, J. A. DiNieri, S. J. Russo, V. Krishnan, S. Chakravarty, J. Peevey, N. Oehrlein, S. Birnbaum, et al. From the Cover: Mania-like behavior induced by disruption of CLOCK PNAS, April 10, 2007; 104(15): 6406 - 6411. [Abstract] [Full Text] [PDF]

				M. Ryan and J. T. Slevin Restless legs syndrome. Am. J. Health Syst. Pharm., September 1, 2006; 63(17): 1599 - 1612. [Abstract] [Full Text] [PDF]

				I. N. Ferrier, L. J. Ferrie, and K. A. Macritchie Old drug, new data: REVISITING... LITHIUM THERAPY Advan. Psychiatr. Treat., July 1, 2006; 12(4): 256 - 264. [Abstract] [Full Text] [PDF]